Alexion Pharmaceuticals, Inc., based in Boston, MA, offers Soliris, a medication that is available exclusively through a restricted program known as the SOLIRIS REMS. This Risk Evaluation and Mitigation Strategy aims to reduce the occurrence and severity of meningococcal infections by providing healthcare providers and patients with essential information about the increased risk associated with Soliris, early signs of invasive meningococcal infections, and the need for immediate medical evaluation. Certification is required for healthcare providers who prescribe Soliris, involving the review of educational materials and enrollment in the SOLIRIS REMS.
Patients using Soliris are provided with comprehensive safety materials, including a Patient Safety Brochure and a Patient Safety Card, which they are advised to carry at all times and present to any healthcare professional involved in their treatment. The safety card contains crucial information about the risk of meningococcal infection that patients need to be aware of before and during their Soliris treatment. Alexion Pharmaceuticals encourages healthcare providers to report any suspected adverse events or cases of meningococcal infection to ensure patient safety.
Generated from the website